

## LIRH VIRTUAL Conference 2020

The current perspectives for the treatment of Huntington's Disease

December 12, 2020h 10.00-13.00 CEST

### PRELIMINARY PROGRAM

#### SESSION 1-10.00-11.20

##### Welcome and Opening

Barbara D'Alessio, Executive Director, LIRH Foundation

Ferdinando Squitieri, Head of the Huntington Research Unit,

Casa Sollievo della Sofferenza Research Hospital – LIRH Foundation Scientific Officer

##### Experience and expectations towards Research

Patients and Family Members

##### Generation HD1

Marco Pacifici, Rare Conditions Partner, Roche

##### Precision HD1 and Precision HD2

Wave Life Science, Speaker to be confirmed

##### Proof-HD

Michael R. Hayden, Chief Executive Officer, Prilenia Therapeutics

#### BREAK 11.20-11.25

#### SESSION 2-11.25-13.00

##### Gene Therapy(ATM-130)

David Cooper, Vice President Clinical Development, UniQure

##### Signal

Maurice Zauderer, President and Chief Executive Office, Vaccinex

##### Q&A and Conclusion

